Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY Anticipated Dispensing Commencement and Flora Sync LF5 Commercial Launch Summer 2026 ...
Daré Bioscience, Inc. ( DARE) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDT [Operator Instructions] We will take our first question from the line of Kemp Dolliver from Brookline Capital Markets.
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results